During the past decade, CHU Cote de Nacre conducted 110 clinical trials. In the 10-year time frame, 110 clinical trials started and 26 clinical trials were completed, i.e. on average, 23.6% percent of trials that started reached the finish line to date. In the past 5 years, 43 clinical trials started and 18 clinical trials were completed. i.e. 41.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CHU Cote de Nacre" #1 sponsor was "Intergroupe Francophone de Cancerologie Thoracique" with 20 trials, followed by "Boehringer Ingelheim" with 11 trials sponsored, "Federation Francophone de Cancerologie Digestive" with 10 trials sponsored, "Assistance Publique - Hôpitaux de Paris" with 8 trials sponsored and "Hoffmann-La Roche" with 8 trials sponsored. Other sponsors include 120 different institutions and companies that sponsored additional 81 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CHU Cote de Nacre" #1 collaborator was "Ministry of Health, France" with 6 trials as a collaborator, "Bristol-Myers Squibb" with 3 trials as a collaborator, "Eli Lilly and Company" with 3 trials as a collaborator, "Janssen-Cilag Ltd." with 3 trials as a collaborator and "Novartis" with 3 trials as a collaborator. Other collaborators include 94 different institutions and companies that were collaborators in the rest 94 trials.

According to Clinical.Site data, the most researched conditions in "CHU Cote de Nacre" are "Multiple Myeloma" (6 trials), "Ulcerative Colitis" (6 trials), "Non Small Cell Lung Cancer Metastatic" (5 trials), "Carcinoma, Non-Small-Cell Lung" (4 trials) and "MDS" (4 trials). Many other conditions were trialed in "CHU Cote de Nacre" in a lesser frequency.

Most popular intervention types in "CHU Cote de Nacre" are "Drug" (120 trials), "Other" (23 trials), "Device" (16 trials), "Procedure" (10 trials) and "Biological" (7 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (15 trials), "Pemetrexed" (7 trials), "Gemcitabine" (6 trials), "Cisplatin" (4 trials) and "Etrolizumab" (4 trials). Other intervention names were less common.

The vast majority of trials in "CHU Cote de Nacre" are 175 trials for "All" genders, 3 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "CHU Cote de Nacre". 4 are not yet recruiting, 39 are recruiting, 25 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 88 completed trials in CHU Cote de Nacre, undefined suspended trials, and 13 terminated clinical trials to date.

Out of the total trials that were conducted in CHU Cote de Nacre, 6 "Phase 1" clinical trials were conducted, 52 "Phase 2" clinical trials and 68 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 12 trials, and there were also 21 trials that are defined as “Not Applicable".